IGF2BP1 and colorectal carcinoma: The expression of IGF2BP1 (probe: 227377_at*) was considered as a top-quality cancer biomarker for classifying chemotherapy responsiveness in this cohort at the strong cutoff (16) (Figure 3D), suggesting that enhanced IGF2BP1 expression may contribute to therapeutic resistance in CRC subpopulations.